News Releases
- December 14, 2021Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics
- November 15, 2021Annovis Bio Announces Transfer of Listing to the New York Stock Exchange
- November 12, 2021Annovis Bio Presented at the 14th Clinical Trials on Alzheimer’s Disease Conference
- November 9, 2021Annovis Bio Presents Poster on Mechanism of Action at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- November 2, 2021Annovis Bio to Present at the 14th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
- October 5, 2021Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease
- September 24, 2021Annovis Bio to Present at the Cantor Global Healthcare Conference
- September 10, 2021Annovis Bio to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- September 3, 2021Annovis Bio Interview to Air on Bloomberg U.S. on the RedChip Money Report®
- August 25, 2021Annovis Bio to Present at Biomarkers for Alzheimer’s Disease Summit 2021
Events & Presentations
-
Annovis Bio - Phase III PD Data
-
AD & PD Data Updates - July 2024
Filings
Filings
Description
Date Filed
Available Formats
E-mail Alerts
Back to Top